PeterD.AplanMD

Physician

Dr. Aplan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
Rockville Pike
# 8901
Bethesda, MD 20889
Phone+1 301-435-5005

Fax+1 301-496-0047

National Capital ConsortiumFellowship, Pediatric Hematology/Oncology, 1987 - 1992
University at BuffaloResidency, Pediatrics, 1983 - 1987
Pennsylvania State University College of MedicineClass of 1983

PubMed

A Call to Arms: Overcoming challenges in Myelodysplastic Syndromes therapy advances.
Kathy L McGraw, Peter D Aplan, Steven Z Pavletic
Seminars in Hematology. 2024-12-01
The DNA Methyltransferase Inhibitor 5-Aza-4'-thio-2'-Deoxycytidine Induces C>G Transversions and Acute Lymphoid Leukemia Development.
Ryan M Bertoli, Yang Jo Chung, Michael J Difilippantonio, Anthony Wokasch, Madison R B Marasco
Cancer Research. 2024-08-01
1 citations
The evolution of preclinical models for myelodysplastic neoplasms.
Alain Mina, Steven Pavletic, Peter D Aplan
Leukemia. 2024-04-01

Abstracts/Posters

Idh2R140Q Cooperates with NHD13 to Induce Immature T Cell Leukemia By Targeting Early T Cell Progenitors or DN2 Thymocytes
Peter D. Aplan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Disruption of the Normal Hematopoietic Hierarchy Leading to Stem Cell Exhaustion in an Animal Model of Myelodysplastic Syndrome
Peter D. Aplan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

A Novel DNA Methyltransferase Inhibitor Is Effective in an In Vivo Model of Myelodysplastic Syndrome
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Mice with a Unique Mutator Phenotype Allow Detection of Lymphoid Leukemia Tumor Suppressor Genes
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Engineered Bcor Mutations Lead to Acute Lymphoblastic Leukemia of Progenitor B-1 Lymphocyte Origin in a Sensitized Background
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
5th Annual T-cell Lymphoma Forum
Jonathan Wood & Associates, San Francisco, California - 1/24/2013
Join now to see all

Pre-Clinical Studies Of Therapy For Myelodysplastic SyndromeNational Cancer Institute2010–2011
Mechanisms Of Chromosomal TranslocationNational Cancer Institute2010–2011
Collaborative Pathways That LEAD To LeukemiaNational Cancer Institute2010–2011
Activation Of Proto-Oncogenes By Chromosomal TranslocationNational Cancer Institute2010–2011
Mechanisms Of Chromosomal TranslocationDivision Of Clinical Sciences - Nci2009
Activation Of Proto-Oncogenes By Chromosomal TranslocationDivision Of Clinical Sciences - Nci2009
Pre-Clinical Studies Of Therapy For Myelodysplastic SyndromeDivision Of Basic Sciences - Nci2009
Collaborative Pathways That LEAD To LeukemiaDivision Of Basic Sciences - Nci2009
Pre-Clinical Studies Of Therapy For Myelodysplastic SyndromeNational Cancer Institute2008
Mechanisms Of Chromosomal TranslocationNational Cancer Institute2007–2008
Activation Of Proto-Oncogenes By Chromosomal TranslocationNational Cancer Institute2007–2008
Activation Of Proto-Oncogenes By Chromosomal TranslocatiDivision Of Clinical Sciences - Nci2002–2006
Mechanisms Of Chromosomal TranslocationDivision Of Clinical Sciences - Nci2001–2006
Activation Of Proto-Oncogenes--Chromosomal TranslocationDivision Of Clinical Sciences - Nci2001
SCL Gene Dysregulation And T Cell LeukemiaNational Cancer Institute1996–1999
Chromosomal Translocations Caused By TOPO II InhibitorsNational Cancer Institute1997–1998